# FDA requests removal of a warning from certain GLP-1 drug labels

> FDA asked manufacturers to remove suicidal behavior and ideation warning language from certain semaglutide, tirzepatide, and liraglutide labels.

- Evidence object: `story:fda-glp1-label-warning-removal-request:v1`
- Evidence domain: Safety
- Date in source: 2026-01-13
- Source checked: 2026-07-29
- Published by PeptideScanner: 2026-07-29
- Story landing page: https://peptidescanner.com/stories/fda-glp1-label-warning-removal-request/
- JSON record: https://peptidescanner.com/evidence/v1/objects/fda-glp1-label-warning-removal-request-v1.json
- Content SHA-256: `260bafd16d6f0d422b8bc70d0a4a4a64bd45ca9d7f424a1ee57a5d3948a9cf00`

## Claims and source pins

### Headline

FDA requests removal of a warning from certain GLP-1 drug labels ([`fda-glp1-label-warning-request-2026`](#source-fda-glp1-label-warning-request-2026))

### Summary

FDA asked manufacturers to remove suicidal behavior and ideation warning language from certain semaglutide, tirzepatide, and liraglutide labels. ([`fda-glp1-label-warning-request-2026`](#source-fda-glp1-label-warning-request-2026))

### Paragraph 1

FDA's communication says the agency requested that manufacturers remove suicidal behavior and ideation warning language from the labels of certain GLP-1 receptor agonist medicines. ([`fda-glp1-label-warning-request-2026`](#source-fda-glp1-label-warning-request-2026))

### Paragraph 2

The FDA communication names Wegovy, Zepbound, and Saxenda. This update reports the agency's labeling request and does not provide an individualized interpretation of safety. ([`fda-glp1-label-warning-request-2026`](#source-fda-glp1-label-warning-request-2026))

## Sources

<a id="source-fda-glp1-label-warning-request-2026"></a>
- **FDA requests removal of suicidal behavior and ideation warning from certain GLP-1 RA labels** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp) (`fda-glp1-label-warning-request-2026`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "FDA requests removal of a warning from certain GLP-1 drug labels." Version 1, published 2026-07-29. https://peptidescanner.com/evidence/v1/objects/fda-glp1-label-warning-removal-request-v1.json SHA-256: 260bafd16d6f0d422b8bc70d0a4a4a64bd45ca9d7f424a1ee57a5d3948a9cf00.